Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Neurodegenerative-focused start-up NeuroBo goes public through reverse merge with Gemphire

Executive Summary

Gemphire Therapeutics Inc. (therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH)) and private neurodegenerative disease start-up NeuroBo Pharmaceuticals Inc. agreed to an all-stock merger that will result in NeuroBo owning approximately 95.94% of the combined company, which will keep the NeuroBo name and business focus and take over Gemphire's Nasdaq listing with a new ticker symbol.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies